Jessica J Lin

Jessica J Lin

UNVERIFIED PROFILE

Are you Jessica J Lin?   Register this Author

Register author
Jessica J Lin

Jessica J Lin

Publications by authors named "Jessica J Lin"

Are you Jessica J Lin?   Register this Author

32Publications

1536Reads

42Profile Views

Time to tackle the blood-brain barrier in HER2-mutant lung cancer.

Cancer 2019 Dec 30;125(24):4363-4366. Epub 2019 Aug 30.

Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32460DOI Listing
December 2019

Imaging Features and Metastatic Patterns of Advanced -Rearranged Non-Small Cell Lung Cancer.

AJR Am J Roentgenol 2019 Dec 30:1-9. Epub 2019 Dec 30.

Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Founders 202, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.19.21982DOI Listing
December 2019

Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity.

Clin Cancer Res 2019 Nov 29;25(22):6662-6670. Epub 2019 Jul 29.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858956PMC
November 2019

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.

Clin Lung Cancer 2019 Oct 16. Epub 2019 Oct 16.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.10.006DOI Listing
October 2019

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

J Thorac Oncol 2019 05 18;14(5):816-824. Epub 2019 Jan 18.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486857PMC
May 2019

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.

J Thorac Oncol 2019 04 7;14(4):683-690. Epub 2018 Dec 7.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183351
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440803PMC
April 2019

Refining precision cancer therapy in ALK-positive NSCLC.

EBioMedicine 2019 Mar 6;41:9-10. Epub 2019 Feb 6.

Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.01.059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444055PMC
March 2019

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

J Thorac Oncol 2018 11;13(11):e226-e227

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183077
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.06.021DOI Listing
November 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 04 31;13(4):550-558. Epub 2018 Jan 31.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183003
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.01.012DOI Listing
April 2018

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Lancet Oncol 2018 04 12;19(4):438-439. Epub 2018 Mar 12.

Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30160-8DOI Listing
April 2018

Recent Advances in Targeting ROS1 in Lung Cancer.

J Thorac Oncol 2017 11 14;12(11):1611-1625. Epub 2017 Aug 14.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659942PMC
November 2017

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 05 11;12(5):872-877. Epub 2017 Jan 11.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403618PMC
May 2017

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discov 2017 02 25;7(2):137-155. Epub 2017 Jan 25.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296241PMC
February 2017

Raising the bar on first-line immunotherapy in lung cancer.

Lancet Oncol 2017 01 5;18(1):2-3. Epub 2016 Dec 5.

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30594-0DOI Listing
January 2017

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2016 11 17;11(11):2027-2032. Epub 2016 Aug 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.126DOI Listing
November 2016

Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?

J Clin Oncol 2016 10 25;34(28):3363-5. Epub 2016 Jul 25.

Massachusetts General Hospital Cancer Center, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.5891DOI Listing
October 2016

Resisting Resistance: Targeted Therapies in Lung Cancer.

Trends Cancer 2016 07;2(7):350-364

Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, 32 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091655PMC
July 2016

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

J Thorac Oncol 2016 Apr 25;11(4):556-65. Epub 2015 Dec 25.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.12.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979601PMC
April 2016

Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer.

Cell Rep 2015 Jun 4;11(10):1549-63. Epub 2015 Jun 4.

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; BBS Program, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; The Broad Institute, Cambridge, MA 02138, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.05.011DOI Listing
June 2015